SecBot SecBot
8-K ·Filed Jul 20, 2026

DYN

Dyne Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001193125-26-308343
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The PDUFA date of January 21, 2027, is the next major catalyst. Traders should monitor for any FDA advisory committee meeting announcements or review updates in the coming months. A positive decision could be transformative for Dyne, while a complete response letter would be a severe setback.

DirectionBullish
Confidencehigh
Horizonmonths

Drug in focus

DYN drug pipeline →

z-rostudirsen

▲ Bullish Named in this 8-K
Impact
Phase
Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
Time to market
Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
Next catalyst
PDUFA date · Jan 21, 2027 65d

What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.45
T+0 close · Jul 20, 2026 · via day close
Latest settled
−34.75%
T+60 · $15.30
Vs SPY
−39.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $23.45entry
  2. T+1 · 4mo ago +1.62%α +0.79% · $23.83
  3. T+5 · 4mo ago +4.22%α +4.65% · $24.44
  4. T+20 · 3mo ago +11.51%α +7.39% · $26.15
  5. T+60 · 5w ago −34.75%α −39.60% · $15.30
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, granted Priority Review with a PDUFA target date of January 21, 2027. The company expects a potential U.S. launch in Q1 2027 if approved, marking a significant regulatory milestone for this clinical-stage biotech.

Key Facts

  • FDA accepted BLA for z-rostudirsen (DYNE-251) for DMD exon 51 skipping
  • Priority Review granted with PDUFA target action date of January 21, 2027
  • Company expects potential U.S. launch in first quarter of 2027, assuming approval

Financial Impact

No financial figures provided in the filing; approval could unlock significant revenue potential in DMD market

Risk Factors

  • FDA may not approve the BLA or may require additional clinical data
  • Potential delays in review timeline or advisory committee outcomes
  • Competition from existing DMD therapies (e.g., Exondys 51, Vyondys 53) and other exon-skipping candidates

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-308343
Document: 0001193125-26-308343-index-headers.html0001193125-26-308343
Document: 0001193125-26-308343-index.html0001193125-26-308343
Document: 0001193125-26-308343.txt0001193125-26-308343

Track record

54 reports on DYN

Performance horizon

11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026